Barbara Pistilli

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

José Baselga, Seock‐Ah Im, Hiroji Iwata et al. · The Lancet Oncology · 2017 · 539 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Denise A. Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard et al. · Advances in Therapy · 2013 · 520 citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Fernanda Mosele, Élise Deluche, Amélie Lusque et al. · Nature Medicine · 2023 · 370 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study

Hatem A. Azim, Niels Kroman, Marianne Paesmans et al. · Journal of Clinical Oncology · 2012 · 249 citations · Full text

Medicine, Obstetrics, Oncology +16

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Arlindo R. Ferreira, Antonio Di Meglio, Barbara Pistilli et al. · Annals of Oncology · 2019 · 223 citations · Full text

Medicine, Endocrinology, Oncology +15